What’s Stopped Me From Buying AstraZeneca Plc Today

Royston Wild considers the investment case for AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I am looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US), and deciding whether to add the company to my personal stocks portfolio.

Patent expiration problems continue to gallop on

AstraZeneca’s half-yearly report released this month showed revenues, on a constant exchange rate, fall 8% in January-June to $12.62bn. This in turn drove core operating profit 16% lower to $4.38bn. The effect of patent expiration across many of its key products moderated in the second quarter, although revenues and core operating profit still fell 4% and 10% in the period.

Promisingly, AstraZeneca announced that its product pipeline had added three promising late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases”. The company is undergoing significant transformation plans at its R&D operations across Europe in order to compensate for the loss of key patents and undergird future earnings growth.

But the firm seems to be behind many of its rivals such as GlaxoSmithKline in significantly addressing the issue of exclusivity loss and bringing online new earnings drivers. The new product additions are a promising development in the firm’s transformation plan, but with new drugs taking years to hit the shelves from initial testing, investors should be braced for more near-term pain.

Earnings slump predicted to last through 2014

City forecasters expect last year’s 12% earnings slump to remain in vogue well into the medium term. Earnings per share are expected to slip 19% this year, to 335p, before falling a further 6% in 2014 to 316p.

The pharma play currently changes hands on a P/E ratio of 9.7 and 10.3 for 2013 and 2014 respectively, figures anchored around the widely-regarded bargain watermark of 10 times prospective earnings. But in my opinion this simply reflects the dearth of earnings catalysts at the firm and thus strong likelihood for shareholder returns to encounter severe pressure.

Pick up the prescription for bountiful gains

On the dividend front, analysts have pencilled in a full-year payout of 285 US cents for 2013, with a rise to 287 cents expected next year. These payments carry yields of 5.7%, comfortably beating the 3.1% FTSE 100 average and aggregate reading of 2.4% for its pharmaceuticals and biotechnology rivals.

AstraZeneca kept the dividend on hold at 280 cents last year as earnings crumbled, and I believe that future dividends could come under fire should further earnings pressure materialise as expected. In my opinion the pharma giant represents too much of a gamble for investors at present, and I will be waiting for more progress from its product pipeline before I consider parting with my cash.

So although AstraZeneca is not a candidate for the savvy investor’s stocklist at present, I believe that you should check out this exclusive, in-depth report about another FTSE 100 high-income opportunity ready to dispense lucrative shareholder returns.

The blue chip in question offers a prospective dividend yield comfortably north of 5%, and has been declared “The Motley Fool’s Top Income Stock For 2013“! Click here to download the report now — it’s absolutely free and comes with no further obligation.

> Royston does not own shares in AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Mother and Daughter Blowing Bubbles
Investing Articles

£20,000 in savings? Here’s how that could be turned into a £34,759 annual second income

Christopher Ruane explains how someone with £20k to invest and a long-term approach could target a substantial annual second income…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

These FTSE 100 shares could soar in the coming year

Amid a turbulent year for the FTSE 100 index, our writer explains why he thinks some of its shares could…

Read more »

Businesswoman calculating finances in an office
Investing Articles

These FTSE 100 passive income stocks have raised their dividends for more than 25 years

Passive income investors can be served by high dividend yields, but multi-year rises in the annual cash payout might even…

Read more »

ISA Individual Savings Account
Investing Articles

3 reasons this May could be a great month to start an ISA, even without a spare £20,000

Christopher Ruane has been taking advantage of recent market volatility to buy shares. Here's why he thinks now might be…

Read more »

British Pennies on a Pound Note
Investing Articles

On the hunt for cheap shares to buy for under a pound, here are 2 I found – again!

Looking for cheap shares to buy, our writer revisits the investment case for two he bought at higher prices. Should…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Can Nvidia stock hit $200 in 2025?

Nvidia stock's traded sideways since last June. Could it be about to enjoy another big move upwards? Edward Sheldon provides…

Read more »

many happy international football fans watching tv
Investing Articles

Déjà vu! The JD Sports share price is sinking again

After a disappointing 12 months, our writer thought the JD Sports Fashion share price had finally turned the corner. But…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

£10,000 invested in the FTSE 100 at the start of the century could now be worth…

Even those who put their money into FTSE 100 stocks during the internet bubble in late 1999 could have built…

Read more »